close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

280.05 -1.22 (-0.43%)
Official Closing Price Updated: 7:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today ↗
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market... 
Via Benzinga
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
News headline image
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript ↗
Organic revenue returned to growth as biopharmaceutical demand strengthened. 
Via The Motley Fool
Topics Earnings
News headline image
5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call
Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management hi... 
Via StockStory
Topics Artificial Intelligence Earnings Economy
Charles River Laboratories (NYSE:CRL) Tops Q2 Estimates and Raises Full-Year Outlook ↗
Via Chartmill
News headline image
Charles River Laboratories International Q2 Earnings Call Highlights ↗
Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and... 
Via MarketBeat
Topics Earnings
News headline image
CRL Q2 Deep Dive: Strategic Portfolio Moves and Biopharma Demand Fuel Margin Expansion
Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 2.7% year on ... 
Via StockStory
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Charles River Laboratories’s (NYSE:CRL) Q2 CY2026 Sales Top Estimates, Stock Soars
Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.7% year... 
Via StockStory
News headline image
Charles River Laboratories Earnings: What To Look For From CRL
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting results this Wednesday before the bell. Here’s what to look for. Charles River L... 
Via StockStory
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
Which S&P500 stocks are gapping on Thursday? ↗
Via Chartmill
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Healthcare Stocks We Approach with Caution
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
3 Reasons to Avoid CRL and 1 Stock to Buy Instead
Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P... 
Via StockStory
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? ↗
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors. 
Via The Motley Fool
News headline image
1 S&P 500 Stock on Our Buy List and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato... 
Via StockStory
Topics Economy
News headline image
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call
Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the i... 
Via StockStory
Topics Earnings
News headline image
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
Charles River Laboratories International Q1 Earnings Call Highlights ↗
Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic... 
Via MarketBeat
Topics Earnings Economy
News headline image
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results ↗
Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.